RAVEENDRA B SURYADEVARA
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry LAS VEGAS, NV NPI 1649280223
Browse related groups: Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry NV Teva Pharmaceuticals USA, Inc. All categories
General Payments — all program years on this page
$929.35
- Category: General Payments
- Program years: PY2018–2024
- Record count: 10
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $768.94 across 7 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $768.94 | 7 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | $180.77 | 2 |
| Neurocrine BioSciences, Inc. | $142.31 | 1 |
| Otsuka America Pharmaceutical, Inc. | $123.90 | 1 |
| E.R. Squibb & Sons, L.L.C. | $117.16 | 1 |
| Alkermes, Inc. | $116.83 | 1 |
| ABBVIE INC. | $87.97 | 1 |
By program year
Records — PY2024 (7)
| Record ID | Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Source |
|---|---|---|---|---|---|---|---|
| 1101292088 | E.R. Squibb & Sons, L.L.C. | $117.16 | 11/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1106185649 | ABBVIE INC. | $87.97 | 03/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1118990238 | Otsuka America Pharmaceutical, Inc. | $123.90 | 10/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1120605123 | Alkermes, Inc. | $116.83 | 04/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1150807007 | Neurocrine Biosciences, Inc. | $142.31 | 09/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1151605956 | Teva Pharmaceuticals USA, Inc. | $80.73 | 12/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1151605958 | Teva Pharmaceuticals USA, Inc. | $100.04 | 12/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.